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In spite of its reputation as a chemosensitive malignancy,
multiple myeloma remains fatal for nearly all those who
contract it. The mortality has changed little in the last 30
years (Feinleib & MacMahon, 1960), although the duration
of the illness has been extended from a median of 7 months
prior to the introduction of chemotherapy to around 2 years
today (a figure which varies between I and 4 years depending
upon the selection of patients) (Alexanian et al., 1969; Durie
& Salmon, 1975; Case et al., 1977; Cooper et al., 1986).
There are, however, some signs that the situation may be
changing. Recent developments in treatment intensification,
maintenance therapy and newer biological approaches all
suggest that in the forseeable future prolonged remissions or
even cures may be obtained, particularly in selected sub-
groups of patients. To define these, a large number of studies
examining prognostic factors have been carried out, with
$-microglobulin levels (Cassuto et al., 1978; Bataille et al.,
1984; Cuzick et al., 1985; Greipp et al., 1988; Dunie et al.,
1990), interleukin 6/C-reactive protein levels (Bataille et al.,
1989; Ludwig et al., 1991a), plasma cell labelling index
(Durie & Bataille, 1989; Greipp et al., 1993), lactate dehyd-
rogenase (Dimopoulos et al., 1991) and thymidine kinase
activity (Brown et al., 1993) all being used to supplement
clinical information on the severity of the disease.
There remain several areas of controversy which require
clarification, principally the relative merits of combination
chemotherapy versus single alkylating agents with prednis-
olone, the place of myeloablative therapy and the role of
interferon. While there is no shortage of information on
conventional and interferon therapy from randomised trials,
much of it is unfortunately contradictory owing to variations
in patient sekction, administration of treatment and
definition of responses. A particular deficit is the lack of a
randomised prospective trial of treatment intensification, and
the seventh Medical Research Council trial in myeloma is
attempting to address this question.
The standard treatment for newly diagnosed myeloma of
stages H and II has previously been the combination of an
alkylating agent (melphalan or cyclophosphamide) with pred-
nisolone given orally in short courses at monthly intervals
(Alexanian et al., 1969). With such an approach around half
of the patients can be expected to show some response, the
exact percentages quoted in different studies depending upon
the degree of reduction in paraprotein or marrow plas-
macytosis required to define a response (Rivers & Patno,
1969; MRC, 1971, 1980; Cooper et al., 1986). The median
duration of remission is of the order of 1-2 years. Initial
reports of combination chemotherapy regimens appeared to
suggest that higher response rates could be achieved and
survival prolonged (Case et al., 1977; Salmon et al., 1983a).
Subsequent studies have not supported this conclusion
(Cooper et al., 1986; Pavlovsky et al., 1988; Peest et at., 1988;
Osterborg et al., 1989; Hjorth et al., 1990), and a recent
meta-analysis of trials including nearly 4,000 patients showed
no consistent benefit for combination treatments when com-
pared with melphalan and prednisolone (Gregory et al.,
1992). However, this overall conclusion should not obscure
important contributions from some combinations: a relatively
small number of trials testing adriamycin-containing
regimens were included in the analysis, limiting its power to
detect benefits from the use of these. Patients in poor prog-
nostic groups appeared to fare better with combination treat-
ment (MacLennan et al., 1992), while those with favourable
features showed longer survival following melphalan and
prednisolone (Peest et al., 1988; Osterborg et al., 1989). This
may relate to the faster and higher response rates which
multi-drug treatments produce, an advantage more likely to
benefit patients with rapid-tempo and widespread disease.
The finding that novel combinations employing infusional
vincristine and adriamycin with high doses of either dex-
amethasone or methylprednisolone (VAD or VAMP) had
significant activity in patients with disease resistant to
alkylating agents (Barlogie et al., 1984; Forgeson et al., 1988)
has led to these regimens increasingly being used as initial
therapy. Although the remissions induced are no more
durable than those following other types of conventional
chemotherapy, the responses are rapid (Samson et al., 1989;
Salmon & Crowley, 1992), and the use of these treatments
for cytoreduction prior to high-dose treatment with
alkylating agents has the theoretical advantage of non-cross-
resistance.
The transience of remissions after conventional treatment
has led to the investigation of dose intensification, following
early work on high-dose melphalan (McElwain & Powles,
1983). In the 30% of patients who present below the age of
60 it has been possible to demonstrate a dose-response
relationship for melphalan. Initially treatment with
140 mg m2 was shown to produce responses in patients
resistant to conventional doses, with complete disappearance
of the paraprotein in one-third (Selby et al., 1987). The use
of autologous bone marrow transplantation to hasten
haematological recovery allowed an increase in the dose of
melphalan to 200mgm-2. This approach, used after induc-
tion with VAMP, resulted in a complete response rate of
50% (Gore et al., 1989).
As myeloablative therapy has become more widely em-
ployed, several features of its use in the treatment of
myeloma have emerged. First, as in studies of non-Hodgkin's
lymphoma (Philip et al., 1987; Gulati et al., 1988), it is
apparent that high-dose therapy is of no appreciable benefit
to patients with refractory disease: although the (partial)
response rates are high, the median duration of remission is
consistently less than 1 year (Barlogie et al., 1986; Gobbi et
al., 1989; Jagannath et al., 1990). Similarly, in those patients
in whom remission is achieved only with difficulty the results
are as poor as for refractory disease (Alexanian et al., 1994).
The best results have been reported for patients receiving
myeloablative treatment at the time of early first remission,
with median survival times extended to over 5 years (Attal et
al., 1992; Cunningham et al., 1994).
With myeloma, unlike lymphoma, virtually all patients
develop recurrent disease after high-dose therapy. Median
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progression-free survival is around 2 years, although
regimens incorporating total body irradiation or allogeneic
transplantation may yield longer disease-free intervals.
Overall survival does not, however, seem to be improved
(Buckner et al., 1989; Gahrton et al., 1991). No study has
formally addressed the impact of total body irradiation, but
data from the French myeloma registry have suggested no
benefit by comparison with chemotherapy-only regimens. The
universal pattern is one of continuous recurrence with no
plateau apparent in remission or survival curves. That recur-
rence is principally attributable to failure of the ablative
treatment rather than reinfusion of viable myeloma cells is
indicated by the lack of prognostic impact of marrow plas-
macytosis in autologous harvests (Barlogie et al., 1986;
Jagannath et al., 1990) and the similar pattern of recurrence
following allogeneic transplant. Studies incorporating ex vivo
purging of autologous bone marrow with either monoclonal
antibodies or chemotherapy have not shown clarly superior
results (Gobbi et al., 1989; Anderson et al., 1993; Reece et
al., 1993), and the use of peripheral blood progenitor cells
seems unlikely to alter the pattern (Bell et al., 1989; Reiffers
et al., 1989; Jagannath et al., 1992). It may be that peripheral
blood in any case contains myeloma precursor cells
(Caligaris-Cappio et al., 1989; Cassel et al., 1990; Omede et
al., 1990; Dreyfus et al., 1993), and the theoretical possibility
of promoting clonal proliferation by the use of colony-
stimulating factors prior to harvesting is also a matter of
concern. There are other advantages to the use of peripheral
blood progenitor cells, principally the reduction in the period
of aplasia (Jagannath et al., 1992; To et al., 1992), which
may allow a broadening of the entry criteria for high-dose
therapy, an important consideration for an illness with
median age at diagnosis of 65.
The selection of patients for treatment intensification re-
mains the crucial determinant of its efficacy. It is disturbing
that myeloablative treatment is insidiously gaining acceptance
as the preferred approach for younger patients without ade-
quate testing of its validity. Preliminary data from the
French collaborative trial IFM-90 are encouraging but by no
means definitive. An interim analysis of the results for 150
patients randomised between completing eight cycles of con-
ventional combination chemotherapy or receiving myelo-
ablative therapy after four conventional treatments showed
higher response rates and survival free from recurrence at a
median follow-up of 30 months (data presented at British
Society of Haematology conference, Harrogate, 1994). While
randomisation between two obviously disparate techniques
may be difficult to explain, it must be acknowledged honestly
that neither is clearly to be preferred: a similar randomisation
has proven possible for the MRC trials in acute leukamia.
The limitations of chemotherapy have encouraged the
investigation of biological treatments. An early report des-
cribed the therapeutic effect of human leucocyte interferon in
patients resistant to conventional treatment (Mellstedt et al.,
1979), and subsequent studies have confirmed responses in
approximately 10% of such patients, compared with around
30% in those previously untreated (Constanzi et al., 1985;
Wagstaff et al., 1985; Cooper, 1991). An intriguing but unex-
plained finding is that patients with IgA myeloma appear to
benefit more than others (Ohno & Kimura, 1986). In general,
the mechanism of action of interferon is poorly understood:
low doses may actually stimulate the proliferation of
myeloma cell lines in vitro (Klein et al., 1990), but higher
doses have direct cytotoxic activity (Creasey et al., 1980;
Salmon et al., 1983; Einhorn et al., 1988). Other possible
effects include the inhibition of autocrine stimulation of
myeloma cells by interleukin 6 (Jernberg-Wiklund et al.,
1991). alteration of oncogene expression (Clemens, 1985),
enhancement of tumour cell histocompatability antigen ex-
pression (Lindahl et al., 1976) and expansion of T-cell
subsets (Lindahl et al., 1972; Einhorn et al., 1982).
The incorporation of interferon into combination therapy
was prompted by studies of cell lines which showed that it
could enhance the cytotoxic effects of melphalan and pred-
nisolone (Welander et al., 1985). The results of clinical trials
have been disappointing: a large randomised study by the
Cancer and Leukemia Group B showed no response or sur-
vival advantage in the addition ofinterferon-m2b to melphalan
and prednisolone (Cooper et al., 1993). A similar-sized study
by the Myeloma Group of Central Sweden showed an imp-
roved response rate using higher doses of natural interferon-
a, although survival was only improved in patients with IgA
and light-chain disease (Osterborg et al., 1993). An interim
analysis of a randomised study of a multiagent regimen
(vincristne/melphalan/cyclophosphamide/prednisolone) with
or without interferon-a2b suggested a modest improvement in
overall survival but with follow-up too short for reliable
interpretation (Ludwig et al., 1991b). An alternative app-
roach has been taken by the Eastern Cooperative Group,
which has reported a high response rate (80%, with 30%
complete responses) using alternating cycles of vincristine/
carmustine/melphalan/cyclophosphamide/prednisolone with
interferon-a2b (Oken et al., 1992). Whether this in turn results
in improved survival will be determined by trials now in
progress. In general, it is difficult to be optimistic about the
use of interferon in the initial treatment of myeloma.
Experimental results suggesting that interferon could
reduce the proliferative capacity ofmyeloma cells (Salmon et
al., 1983b), and evidence from its use in chronic myeloid
leukaemia that lymphoid stem cell populations might be
attenuated (Bergsagel et al., 1986) led to trials of interferon
as maintenance following chemotherapy. An initial report
from Italy of 101 patients who were randomised to observa-
tion or interferon maintenance after 12 months' conventional
chemotherapy indicated an improvement in duration of
remission and of survival (from a median of 39 to 52
months), an effect confined to those in whom initial
chemotherapy had produced a reduction in paraprotein of
over 50% (Mandelli et al., 1990). A similar report by the
Myeloma Group of Western Sweden of 120 patients random-
ised after showing a reponse to conventional therapy demon-
strated a prolongation of remission, albeit from an unusually
low 6 months in the observation arm to 14 months (Westin
et al., 1991). No survival data have yet emerged from this
study. In contrast, the Myeloma group of Central Sweden
was unable to show any benefit from the addition of
interferon to maintenance melphalan (Osterborg & Mell-
stedt, 1991), and the Southwest Oncology Group comparing
observation to interferon in 210 responding patients after
combination chemotherapy found no benefit, although the
follow-up was only a median 10 months (Salmon & Crowley,
1992). The most promising data have come from studies of
interferon maintenance following myeloablative therapy: a
phase H study of 63 patients employing high-dose melphalan
with total body irradiation and autologous bone marrow
rescue before introduction of interferon yielded an 81% sur-
vival rate at 42 months from diagnosis (Fermand et al.,
1993). More recently, a randomised trial has shown improved
progression-free survival following high-dose melphalan and
autologous bone marrow rescue in 84 patients, with the
median increased from 27 to 39 months (Cunningham et al.,
1993). The intuitive suggestion that biological treatment is
most likely to be effective as maintenance therapy appears to
be borne out in these studie although clearly more mature
data are needed for reliable interpretation.
As an understanding of the biology of myeloma develops
so newer approaches to its therapy are emerging. In parti-
cular, the identification of interleukin 6 (IL-6) as an impor-
tant growth promoter in plasma cells (Zhang et al., 1989;
Klein et al., 1990) has led to trials of anti-IL-6 blocking
antibodies (Klein et al., 1991) and -tinterferon (Portier et al.,
1993) or retinoic acid (Sidell et al., 1991) for down-regulation
of the IL-6 receptor. The importance of multidrug resistance
(MDR) gene expression is also under investigation since the
observation that levels increase following chemotherapy (Dal-
ton et al., 1989; Epstein et al., 1989; Salmon et al., 1989;
Grogan et al., 1993), although it has not always proven
possible to correlate its expression with resistance to treat-
ment (Cornelissen et al., 1994). Attempts at sensitisation with
calcium channel blockers have been disappointing (Salmon etTHE TREATMENT OF MULTIPLE MYELOMA 783
al.. 1990). although cyclosporin A showed some promise in
early studies (Sonneveld et al.. 1992) and a new generation of
P-glycoprotein modulators is being tested now.
The question examined in the MRC VIIth myelomatosis
trial is the efficacy of two alternative approaches to treat-
ment. In one arm intensive induction therapy with VAMP
will be followed by high-dose melphalan with autologous
haemopoietic stem cell support from peripheral blood or
bone marrow. This will be compared with the ABCM
regimen of myeloma VI. which is widely used in the UK as
the standard for patients below the age of 65. Maintenance
interferon is used in both arms. The trial is of flexible design
and addresses both survival and quality of life. We hope that
all centres which can use these approaches will join the trial
to allow proper testing of powerful but potentially hazardous
therapy. rather than encourage its indiscnrminate use without
timely and badly needed evaluation.
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